生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

休市中 06-18 16:00:00 EDT

1,128.80

-6.69

-0.59%

最高1,150.72	最低1,118.99	成交量68.56亿
今开1,135.51	昨收1,135.49	日振幅2.79%
总市值0.00	流通市值0.00	总股本0.00
成交额355.59亿	换手率--	流通股本0.00
市净率6.881147	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1128.7953,"timestamp":1781812799999,"preClose":1135.4877,"halted":0,"volume":6856279763,"delay":0,"changeRate":-0.005894,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-6.692383,"latestTime":"06-18 16:00:00 EDT","open":1135.5082,"high":1150.7206,"low":1118.9883,"amount":35559496523.33144,"amplitude":0.027946,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1782115200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.881147,"peRate":-153.406997,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"1106153135","title":"Ultragenyx 根据纳斯达克上市规则授予员工入职激励股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1106153135","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106153135?lang=zh_cn&edition=full","pubTime":"2026-06-20 04:30","pubTimestamp":1781901039,"startTime":"0","endTime":"0","summary":"专注于研发和商业化罕见及超罕见疾病创新疗法的生物制药公司 Ultragenyx Pharmaceutical Inc. 今日宣布，根据纳斯达克上市规则 5635，公司已向 15 名新入职的非高管人员授予了 44,409 份公司普通股限制性股票单位。该奖项由公司董事会薪酬委员会批准，依据 Ultragenyx 员工入职激励计划授予，授予日期为 2026 年 6 月 16 日，旨在作为吸引新员工加入公司的重要激励措施。Ultragenyx 的战略立足于高效、经济的药物开发，目标是以最快的速度向患者提供安全有效的疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","BK4139","RARE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153818649","title":"据《金融时报》报道，根据正在讨论的协议条款，艾伯维将以109亿美元现金收购Apogee股东股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1153818649","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153818649?lang=zh_cn&edition=full","pubTime":"2026-06-19 22:18","pubTimestamp":1781878704,"startTime":"0","endTime":"0","summary":"据《金融时报》披露，一项正在磋商中的交易条款显示，制药巨头艾伯维公司（AbbVie）拟以总计109亿美元的现金，收购生物科技公司Apogee Therapeutics的股东股权。此举若最终落地，将标志着艾伯维在其核心免疫学领域之外，进一步强化其在创新生物制剂领域的布局。市场分析人士指出，这笔潜在的巨额交易凸显了大型制药企业对于拥有前景管线的生物技术公司的强烈收购意愿，旨在补充自身产品线并驱动未来增长。目前，双方尚未就交易细节发表正式评论，后续进展值得密切关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800379.SGD","LU0553294199.USD","IE000F7OJYX1.SGD","LU0985320562.USD","IE0004445239.USD","LU0472753341.HKD","BK4559","LU1551013342.USD","BK4139","LU1057294990.SGD","IE000BZT7R73.USD","LU2357627491.SGD","LU2129689431.USD","IE0000B7K699.USD","LU0861579265.USD","LU0511384066.AUD","LU1496350171.SGD","LU2237443382.USD","LU1670628061.USD","SG9999003800.SGD","IE00BLSP4452.SGD","LU0289739699.SGD","LU2237443622.USD","LU0820561909.HKD","LU0158827948.USD","IE00BLSP4239.USD","LU1989772923.USD","LU2129689514.USD","LU0942090050.USD","IE00BGHQF631.EUR","LU0211327993.USD","LU0795875169.SGD","LU1430594728.SGD","BK4566","LU1934455863.HKD","LU0689626769.HKD","LU0234570918.USD","LU0057025933.USD","LU0965508806.USD","LU1934455277.USD","LU0289961442.SGD","LU0029864427.USD","IE00B42XCP33.USD","LU1989771016.USD","IE00B19Z3581.USD","LU1003077747.HKD","IE00BFTCPJ56.SGD","IE000SO60NU8.SGD","ABBV","IE00BJJMRZ35.SGD","LU0965509283.SGD","LU2237443895.HKD","IE00BDGV0183.EUR","LU2237443978.SGD","LU0098860793.USD","LU1670627923.USD","LU1023059063.AUD","IE00BN8TJ469.HKD","LU1074936037.SGD","LU0820561818.USD","LU0456855351.SGD","IE00B19Z3B42.SGD","LU1989772840.SGD","SG9999015945.SGD","BK4588","LU0069063385.USD","IE00B2B36J28.USD","LU2112291526.USD","IE0002270589.USD","LU0949170772.SGD","SG9999015952.SGD","IE00BVYPNV92.GBP","LU0859254822.USD","LU2087621335.USD","LU0708994859.HKD","IE00BBT3K403.USD","IE0009355771.USD","LU0432979614.USD","LU0868494617.USD","LU0661504455.SGD","IE00B3PB1722.GBP","LU0965509010.AUD","LU0965509101.SGD","SG9999015986.USD","LU0738911758.USD","LU0058720904.USD","LU2237443549.SGD","BK4550","LU1929549753.HKD","LU1267930573.SGD","LU2468319806.SGD","IE00BSNM7G36.USD","LU1037948897.HKD","LU0912757837.SGD","IE00B4R5TH58.HKD","LU0823416689.USD","LU0211328371.USD","LU0943347566.SGD","BK4581","LU1037948541.HKD","LU1061106388.HKD","LU2023251221.USD","LU0868494708.USD","LU0234572021.USD","LU1732799900.SGD","LU0795875086.SGD","LU0289739343.SGD","LU0689472784.USD","IE00BJT1NW94.SGD","LU1244550494.USD","LU0320765646.SGD","LU0170899867.USD","SG9999015978.USD","LU2133065610.SGD","LU0124676726.USD","LU1585245621.USD","SG9999001440.SGD","LU2129689605.HKD","LU0198837287.USD","LU1983299246.USD","LU1732800096.USD","IE00BVYPNW00.USD","LU1093756325.SGD","LU0882574055.USD","LU2347655156.SGD","LU1244550577.SGD","LU0203347892.USD","LU1244550221.USD","LU0256863902.USD","LU1093756168.USD","SG9999011175.SGD","IE000WAW04H5.SGD","BK4534","LU2089284900.SGD","LU1718418525.SGD","LU1291159041.SGD","LU1934455194.USD","LU1162221912.USD","LU1551013425.SGD","LU0545039389.USD","LU1267930490.SGD","IE0002141913.USD","LU2089984988.USD","BK4533","LU1839511570.USD","LU0256863811.USD","LU0417517546.SGD","IE000MB6IJN5.SGD","LU2089283258.USD","LU0122379950.USD","LU0128525929.USD","LU0310799852.SGD","LU1496350502.SGD","LU2237443465.HKD","LU0114720955.EUR","LU0203345920.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125254391","title":"因塞特医疗日本公司宣布Minjuvi®（Tafasitamab）联合来那度胺获准用于治疗复发或难治性弥漫性大B细胞淋巴瘤成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1125254391","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125254391?lang=zh_cn&edition=full","pubTime":"2026-06-19 14:00","pubTimestamp":1781848817,"startTime":"0","endTime":"0","summary":"因塞特医疗的日本子公司宣布，其药物Minjuvi®（通用名：Tafasitamab）联合来那度胺的治疗方案，已获得监管批准，用于治疗复发或难治性弥漫性大B细胞淋巴瘤的成年患者。该疗法为这一特定患者群体提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4588","BK4585","BK4550","BK4532","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644224058","title":"鼓声一响 DNA动了！龙舟划过千年 依然让人心潮澎湃","url":"https://stock-news.laohu8.com/highlight/detail?id=2644224058","media":"央视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644224058?lang=zh_cn&edition=full","pubTime":"2026-06-19 11:49","pubTimestamp":1781840940,"startTime":"0","endTime":"0","summary":"鼓角齐鸣云水间，龙舟列阵竞千帆。端午佳节，各地龙舟赛轮番登场。水面群龙竞逐，鼓鸣浪涌，长桨齐挥，舟行如飞。将节日氛围推向高潮。\n　　千年以来，龙舟竞渡早已融入端午文脉。声声鼓韵穿越时空，踏浪而来，让同舟共济、奋勇争先的民族精神传承不息。\n　　责任编辑：汤嘉铭\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：石秀珍 SF183","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-06-19/doc-inicxcvc9831784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4109","BK4121","DNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644887058","title":"RootData：ALT 将于一周后解锁价值约 172 万美元的代币","url":"https://stock-news.laohu8.com/highlight/detail?id=2644887058","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644887058?lang=zh_cn&edition=full","pubTime":"2026-06-19 11:00","pubTimestamp":1781838005,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据Web3资产数据平台 RootData 代币解锁数据，AltLayer（ALT）将于北京时间 06 月 26 日 8 时解锁约 24659 万枚代币，价值约 172 万美元。 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2272359","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","BK4599","BK4139","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142868924","title":"Moderna股价因流感疫苗获推荐而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1142868924","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142868924?lang=zh_cn&edition=full","pubTime":"2026-06-19 05:32","pubTimestamp":1781818378,"startTime":"0","endTime":"0","summary":"Moderna, Inc. 股价周四上涨3.5%，此前一个顾问委员会投票建议美国食品药品监督管理局批准这家生物技术公司针对50岁及以上人群提出的新型流感疫苗。\n美国食品药品监督管理局最初拒绝受理Moderna的疫苗审批申请，但在该公司修改申请后，同意进行审查。顾问委员会的赞成票虽不具约束力，但食品药品监督管理局通常会采纳此类建议。最终决定预计将在八月初做出。\n正试图拓展新冠疫苗以外业务的Moderna，其股价收盘时创下自2024年9月以来的最高水平。在过去六个交易日中，该股已累计上涨39%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","MRNY","BK4551","BK4533","BK4588","BK4568","BK4585","BK4548","BK4534","MRNA","BK4139","BK4532","BK4501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135687202","title":"MapLight Therapeutics, Inc.声明：Setia离职无权获得任何遣散费","url":"https://stock-news.laohu8.com/highlight/detail?id=1135687202","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135687202?lang=zh_cn&edition=full","pubTime":"2026-06-19 05:07","pubTimestamp":1781816835,"startTime":"0","endTime":"0","summary":"MapLight Therapeutics, Inc.发布声明称，根据相关协议条款，Setia先生因其离职行为，无权获得任何形式的遣散费用。公司强调，此举严格遵循了既定的雇佣合同与内部政策规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MPLT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120487795","title":"Senti Biosciences - 出售股东拟转售1597万股普通股 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1120487795","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120487795?lang=zh_cn&edition=full","pubTime":"2026-06-19 05:07","pubTimestamp":1781816831,"startTime":"0","endTime":"0","summary":"Senti Biosciences公司向美国证券交易委员会（SEC）提交文件，披露一名出售股东计划转售其持有的约1597万股公司普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","SNTI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156015941","title":"MapLight Therapeutics首席财务官Vishwas Setia于2026年6月18日起即刻离职 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1156015941","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156015941?lang=zh_cn&edition=full","pubTime":"2026-06-19 05:03","pubTimestamp":1781816596,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会(SEC)的文件，生物制药公司MapLight Therapeutics, Inc.宣布，其首席财务官Vishwas Setia已于2026年6月18日即刻卸任。\n该文件显示，Setia的离职自2026年6月18日起立即生效。目前，公司尚未公布其首席财务官职位的继任计划。此次人事变动通过SEC的正式文件对外披露，标志着公司管理层的一次重要调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MPLT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105191515","title":"Iovance Biotherapeutics 提交补充招股书，拟增发普通股筹资上限约8970万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105191515","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105191515?lang=zh_cn&edition=full","pubTime":"2026-06-19 04:35","pubTimestamp":1781814938,"startTime":"0","endTime":"0","summary":"Iovance Biotherapeutics公司已提交了一份销售协议补充招股说明书，计划增发普通股，最高筹资额约为8970万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IOVA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157983848","title":"Twist Bioscience Corp：公布普通股销售协议招股说明书，拟不定期发行至多2亿美元股票","url":"https://stock-news.laohu8.com/highlight/detail?id=1157983848","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157983848?lang=zh_cn&edition=full","pubTime":"2026-06-19 04:14","pubTimestamp":1781813651,"startTime":"0","endTime":"0","summary":"Twist Bioscience公司已提交一份销售协议招股说明书，内容涉及一项不定期发行普通股的计划，该计划总筹资额度最高可达2亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","TWST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163979178","title":"Moderna宣布FDA咨询委员会一致支持其季节性流感候选疫苗mRNA-1010的获益-风险特征","url":"https://stock-news.laohu8.com/highlight/detail?id=1163979178","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163979178?lang=zh_cn&edition=full","pubTime":"2026-06-19 04:03","pubTimestamp":1781813033,"startTime":"0","endTime":"0","summary":"Moderna公司表示，美国食品药品监督管理局（FDA）的咨询委员会已一致投票，支持其研究性季节性流感疫苗mRNA-1010的获益-风险特征。这一积极进展为这款基于mRNA技术的流感疫苗后续的监管审评流程奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","BK4139","BK4588","BK4551","BK4585","MRNY","BK4532","MRNX","MRNA","BK4548","BK4568","BK4534","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146627967","title":"CervoMed宣布根据纳斯达克规则进行1000万美元普通股市场价注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1146627967","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146627967?lang=zh_cn&edition=full","pubTime":"2026-06-19 00:36","pubTimestamp":1781800571,"startTime":"0","endTime":"0","summary":"CervoMed宣布，将根据纳斯达克规则进行一项价值1000万美元的普通股注册直接发行，发行价格将按市场价确定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644082762","title":"渤健(BIIB)最高10亿美元收购RayThera 持续加码自身免疫学管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2644082762","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644082762?lang=zh_cn&edition=full","pubTime":"2026-06-18 23:17","pubTimestamp":1781795862,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物制药巨头渤健  达成收购私营生物科技企业 RayThera 的交易，整体交易对价上限 10 亿美元，交易结构由前期预付款与多阶段临床、监管里程碑分成款项构成，交易完成后将全面补强渤健自身免疫疾病产品矩阵。消息公布周四盘前，渤健股价小幅上涨 0.5%，前一交易日收盘涨幅 1.6%。RayThera 核心管线储备多款抗炎候选药物，适配各类免疫介导类疾病治疗，企业核心候选分子预计今年三季度初启动一期临床开发。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MjU4MmU0MDcxNDc2ODE0Nzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301712","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9P08.USD","LU0889565916.HKD","BK4585","BK4139","BK4533","LU0109394709.USD","LU0320765992.SGD","IE00B894F039.SGD","BIIB","IE00B19Z9Z06.USD","BK4532","BK4588","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644108640","title":"百济神州(06160)：授出购股权、受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2644108640","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644108640?lang=zh_cn&edition=full","pubTime":"2026-06-18 21:11","pubTimestamp":1781788297,"startTime":"0","endTime":"0","summary":"于2026年6月11日，董事会、薪酬委员会及╱或首席执行官按照授权根据2016期权及激励计划的条款向8555名承授人授予合共1,499,134股美国存托股份受限制股份单位，并向32名承授人授予于完成目标100%时合共161,039股美国存托股份业绩股份单位。该等受限制股份单位及业绩股份单位合共相当于21,582,249股股份，约占本公告之日公司发行股份总数的1.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1719994722.HKD","LU0307460666.USD","BK1500","ONC","688235","BK1588","BK1583","BK4588","BK4585","LU1770034418.SGD","LU1251922891.USD","LU1969619763.USD","06160","LU0588546209.SGD","LU2328871848.SGD","BK4139","LU1303224171.USD","BK4526","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109491709","title":"Quoin Pharmaceuticals完成日本子公司设立，推进QRX003商业化准备","url":"https://stock-news.laohu8.com/highlight/detail?id=1109491709","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109491709?lang=zh_cn&edition=full","pubTime":"2026-06-18 21:10","pubTimestamp":1781788201,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd宣布已完成日本子公司的设立，此举旨在为其候选药物QRX003的商业化进程做好前期准备。公司计划在2026年下半年启动QRX003的三期临床试验，并有望在2027年提交新药上市申请。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126055655","title":"AIM ImmunoTech提交文件，拟由售股股东发售及转售至多1308万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1126055655","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126055655?lang=zh_cn&edition=full","pubTime":"2026-06-18 21:09","pubTimestamp":1781788194,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech Inc. 已向美国证券交易委员会提交相关文件。根据该文件，公司计划由售股股东进行一项股票发售与转售行动，涉及股份数量最高可达1308万股普通股。此举旨在为现有股东提供流动性选项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AIM","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169183823","title":"Lixte Biotechnology Holdings Inc. 更新Nomad收购案进展；交易预计于2026年7月1日左右完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1169183823","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169183823?lang=zh_cn&edition=full","pubTime":"2026-06-18 20:33","pubTimestamp":1781786038,"startTime":"0","endTime":"0","summary":"Lixte Biotechnology Holdings Inc. 就其收购Nomad公司的交易提供了最新进展。该笔交易预计将于2026年7月1日或大约该日期完成交割。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149934769","title":"MAIA Biotechnology启动新型端粒靶向药物二期扩展试验患者招募，合作机构为埃默里大学Winship癌症研究所","url":"https://stock-news.laohu8.com/highlight/detail?id=1149934769","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149934769?lang=zh_cn&edition=full","pubTime":"2026-06-18 20:31","pubTimestamp":1781785882,"startTime":"0","endTime":"0","summary":"MAIA Biotechnology公司宣布，已启动其新型端粒靶向药物二期临床试验扩展阶段的患者招募工作。此项试验将在埃默里大学Winship癌症研究所进行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MAIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159815510","title":"BioRestorative Therapies任命医疗高管Zach Smith为生物化妆品部门副总裁，以强化领导层并加速商业扩张与战略增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1159815510","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159815510?lang=zh_cn&edition=full","pubTime":"2026-06-18 20:16","pubTimestamp":1781784991,"startTime":"0","endTime":"0","summary":"BioRestorative Therapies, Inc.（BRTX）宣布任命医疗行业资深人士Zachary Smith担任其生物化妆品部门副总裁。这一关键人事任命旨在加强公司领导团队实力，从而加速该部门的商业扩张步伐与整体战略增长。Smith先生将负责推动生物化妆品业务线的商业化进程，并制定与执行长期增长战略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}